Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Thalassemia Treatment Market

Chapter 4. Market Overview
4.1. Introduction
       4.1.1. Treatment Type Definition
       4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
       4.3.1. Drivers
       4.3.2. Restraints
       4.3.3. Opportunity
4.4. Global Thalassemia Treatment Market Analysis and Forecasts, 2016–2026
       4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
4.6. Market Outlook
4.7. Pipeline of Thalassemia Treatment
4.8. Prevalence & Demography - Thalassemia Disease - by Region/Country
       4.8.1. North America
       4.8.2. Europe
       4.8.3. Asia Pacific
       4.8.4. Latin America
       4.8.5. Middle East & Africa
4.9. Cost of Treatment-By Region/Country
       4.9.1. North America
       4.9.2. Europe
       4.9.3. Asia Pacific
       4.9.4. Latin America
       4.9.5. Middle East & Africa
4.10. Prevalent Treatment Regimens - By Country/Region
       4.10.1. Asia Pacific
       4.10.2. Middle East & Africa
4.11. List of Major Hospitals for Thalassemia Treatment - By Region/ Country/State
       4.11.1. North America
       4.11.2. Europe
       4.11.3. Asia Pacific
       4.11.4. Latin America
       4.11.5. Middle East & Africa
4.12. Regulatory Scenario, by Region
       4.12.1. North America
       4.12.2. Europe
       4.12.3. Asia Pacific

Chapter 5. Global Thalassemia Treatment Market Analysis and Forecasts, by Treatment Type
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Market Value Forecast, by Treatment Type, 2016–2026
       5.3.1. Blood Transfusion
       5.3.2. Chelation Therapy
       5.3.3. Bone Marrow Transplant
       5.3.4. Others
5.4. Market Attractiveness, by Treatment Type

Chapter 6. Global Thalassemia Treatment Market Analysis and Forecasts, by Region
6.1. Key Findings
6.2. Market Value Forecast, by Region
       6.2.1. North America
       6.2.2. Europe
       6.2.3. Asia Pacific
       6.2.4. Latin America
       6.2.5. Middle East & Africa
6.3. Market Attractiveness, by Country/Region

Chapter 7. North America Thalassemia Treatment Market Analysis and Forecast
7.1. Introduction
       7.1.1. Key Findings
7.2. Market Value Forecast, by Treatment Type, 2016–2026
       7.2.1. Blood Transfusion
       7.2.2. Chelation Therapy
       7.2.3. Bone Marrow Transplant
       7.2.4. Others
7.3. Market Value Forecast, by Country, 2016–2026
       7.3.1. U.S.
       7.3.2. Canada
7.4. Market Attractiveness Analysis
       7.4.1. By Treatment Type
       7.4.2. By Country

Chapter 8. Europe Thalassemia Treatment Market Analysis and Forecast
8.1. Introduction
       8.1.1. Key Findings
8.2. Market Value Forecast, by Treatment Type, 2016–2026
       8.2.1. Blood Transfusion
       8.2.2. Chelation Therapy
       8.2.3. Bone Marrow Transplant
       8.2.4. Others
8.3. Market Value Forecast, by Country/Sub-region, 2016–2026
       8.3.1. Germany
       8.3.2. U.K.
       8.3.3. France
       8.3.4. Spain
       8.3.5. Italy
       8.3.6. Rest of Europe
8.4. Market Attractiveness Analysis
       8.4.1. By Treatment Type
       8.4.2. By Country/Sub-region

Chapter 9. Asia Pacific Thalassemia Treatment Market Analysis and Forecast
9.1. Introduction
       9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2016–2026
       9.2.1. Blood Transfusion
       9.2.2. Chelation Therapy
       9.2.3. Bone Marrow Transplant
       9.2.4. Others
9.3. Market Value Forecast, by Country/Sub-region, 2016–2026
       9.3.1. China
       9.3.2. India
       9.3.3. ASEAN countries
       9.3.4. Rest of Asia Pacific
9.4. Market Attractiveness Analysis
       9.4.1. By Treatment Type
       9.4.2. By Country/Sub-region

Chapter 10. Latin America Thalassemia Treatment Market Analysis and Forecast
10.1.Introduction
       10.1.1. Key Findings
10.2.Market Value Forecast, by Treatment Type, 2016–2026
       10.2.1. Blood Transfusion
       10.2.2. Chelation Therapy
       10.2.3. Bone Marrow Transplant
       10.2.4. Others
10.3.Market Value Forecast, by Country/Sub-region, 2016–2026
       10.3.1. Brazil
       10.3.2. Mexico
       10.3.3. Rest of Latin America
10.4.Market Attractiveness Analysis
       10.4.1. By Treatment Type
       10.4.2. By Country/Sub-region

Chapter 11. Middle East & Africa Thalassemia Treatment Market Analysis and Forecast
11.1.Introduction
       11.1.1. Key Findings
11.2.Market Value Forecast, by Treatment Type, 2016–2026
       11.2.1. Blood Transfusion
       11.2.2. Chelation Therapy
       11.2.3. Bone Marrow Transplant
       11.2.4. Others
11.3.Market Value Forecast, by Country/Sub-region, 2016–2026
       11.3.1. GCC countries
       11.3.2. South Africa
       11.3.3. Rest of Middle East & Africa
11.4.Market Attractiveness Analysis
       11.4.1. By Treatment Type
       11.4.2. By Country/Sub-region

Chapter 12. Competition Landscape
12.1.Market Player - Market Presence (2017)
       12.1.1. Current Offerings
       12.1.2. Strategy
12.2.Company Profiles
       12.2.1. bluebird bio, Inc.
                 12.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                 12.2.1.2. Product Portfolio
                 12.2.1.3. SWOT Analysis
                 12.2.1.4. Financial Overview
                 12.2.1.5. Strategic Overview
       12.2.2. Acceleron Pharma, Inc.
                 12.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                 12.2.2.2. Product Portfolio
                 12.2.2.3. SWOT Analysis
                 12.2.2.4. Financial Overview
                 12.2.2.5. Strategic Overview
       12.2.3. Novartis AG
                 12.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                 12.2.3.2. Product Portfolio
                 12.2.3.3. SWOT Analysis
                 12.2.3.4. Financial Overview
                 12.2.3.5. Strategic Overview
       12.2.4. Celgene Corporation
                 12.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                 12.2.4.2. Product Portfolio
                 12.2.4.3. SWOT Analysis
                 12.2.4.4. Financial Overview
                 12.2.4.5. Strategic Overview
       12.2.5. Shire Plc. (Takeda Pharmaceuticals)
                 12.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                 12.2.5.2. Product Portfolio
                 12.2.5.3. SWOT Analysis
                 12.2.5.4. Financial Overview
                 12.2.5.5. Strategic Overview
       12.2.6. Incyte Corporation
                 12.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                 12.2.6.2. Product Portfolio
                 12.2.6.3. SWOT Analysis
                 12.2.6.4. Financial Overview
                 12.2.6.5. Strategic Overview
       12.2.7. Kiadis Pharma
                 12.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                 12.2.7.2. Product Portfolio
                 12.2.7.3. SWOT Analysis
                 12.2.7.4. Financial Overview
                 12.2.7.5. Strategic Overview
       12.2.8. Bellicum Pharmaceuticals
                 12.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                 12.2.8.2. Product Portfolio
                 12.2.8.3. SWOT Analysis
                 12.2.8.4. Financial Overview
                 12.2.8.5. Strategic Overview
       12.2.9. GlaxoSmithKline plc
                 12.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                 12.2.9.2. Product Portfolio
                 12.2.9.3. SWOT Analysis
                 12.2.9.4. Financial Overview
                 12.2.9.5. Strategic Overview
       12.2.10. Others

List of Tables

Table 01: Global Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 02: Global Thalassemia Treatment Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 03: North America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 04: North America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 05: U.S. Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 06: Canada Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 07: Europe Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 08: Europe Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 09: U.K. Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 10: Germany Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016-2026
Table 11: France Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 12: Italy Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 13: Spain Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 14: Rest of Europe Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 15: Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 16: Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 17: India Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 18: China Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 19: ASEAN Countries Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 20: Rest of Asia Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 21: Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 23: Brazil Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 24: Mexico Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 25: Rest of Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 26: Middle East & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 27: Middle East & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 28: South Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 29: GCC Countries Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 30: Rest of Middle East & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026

List of Figures

FIG 01: Global Thalassemia Treatment Market Size (US$ Mn) Forecast, 2016–2026
FIG 02: Global Thalassemia Treatment Market Value Share, by Region (2017)
FIG 03: Global Thalassemia Treatment Market Value Share, by Treatment Type (2017)
FIG 04: Global Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
FIG 05: Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Blood Transfusion, 2017–2026
FIG 06: Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Chelating Therapy, 2017–2026
FIG 07: Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Bone Marrow Transplant, 2017–2026
FIG 08: Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2017–2026
FIG 09: Global Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
FIG 10: Global Thalassemia Treatment Market Value Share, by Region, 2018 and 2026
FIG 11: Global Thalassemia Treatment Market Attractiveness, by Region, 2018–2026
FIG 12: North America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2026
FIG 13: North America Thalassemia Treatment Market Value Share, by Country, 2018–2026
FIG 14: North America Thalassemia Treatment Market Attractiveness, by Country, 2018–2026
FIG 15: North America Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
FIG 16: North America Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
FIG 17: Europe Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2026
FIG 18: Europe Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
FIG 19: Europe Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
FIG 20: Europe Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
FIG 21: Europe Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
FIG 22: Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2026
FIG 23: Asia Pacific Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
FIG 24: Asia Pacific Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
FIG 25: Asia Pacific Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
FIG 26: Asia Pacific Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
FIG 27: Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2026
FIG 28: Latin America Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
FIG 29: Latin America Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
FIG 30: Latin America Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
FIG 31: Latin America Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
FIG 32: Middle east & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2026
FIG 33: Middle East & Africa Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
FIG 34: Middle East & Africa Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
FIG 35: Middle East & Africa Thalassemia Treatment Market Value Share, by Treatment Type , 2018 and 2026
FIG 36: Middle East & Africa Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
FIG 37: Global Thalassemia Treatment Market Performance, by Company, 2017
FIG 38: bluebird bio, Inc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 39: bluebird bio, Inc., Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 40: bluebird bio, Inc., Breakdown of Revenue Generation (US$ Mn), by Collaboration, 2014-2017
FIG 41: bluebird bio, Inc., Breakdown of R&D Cost to Company (%), by Products in Pipeline, 2017
FIG 42: Acceleron Pharma, Inc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 43: Acceleron Pharma, Inc., Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 44: Acceleron Pharma, Inc., Breakdown of Revenue Generation (US$ Mn), by Collaboration, 2014-2017
FIG 45: Acceleron Pharma, Inc., Breakdown of R&D Cost to Company (%), by Products in Pipeline, 2017
FIG 46: Novartis AG, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 47: Novartis AG, Research & Development (US$ Mn) and Marketing & Sales (US$ Mn)– Company Level, 2016–2017
FIG 48: Novartis AG, Net Sales (%), by Oncology Business Units, 2017
FIG 49: Novartis AG, Net Sales (%), by Business Segment, 2017
FIG 50: Incyte Corporation, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 51: Incyte Corporation, Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 52: Incyte Corporation, Breakdown of Revenue Generation (US$ Mn), by Royalties, 2014-2017
FIG 53: Incyte Corporation, Breakdown of Sales (%), by Products, 2017
FIG 54: Kiadis Pharma, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 55: Kiadis Pharma, Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 56: Kiadis Pharma, Breakdown of Revenue Generation (US$ Mn), by Operating and Investing Activities, 2016-2017
FIG 57: Kiadis Pharma, Breakdown of Operating Cost to Company (%), 2016 and 2017
FIG 58: Shire plc, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 59: Shire plc, Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 60: Shire plc, Breakdown of Revenue Generation (%), by Region/Country, 2017
FIG 61: Shire plc, Breakdown of Product Sales to Company (%), 2017
FIG 62: Celgene Corporation, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 63: Celgene Corporation, Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 64: Celgene Corporation, Breakdown of Revenue Generation (US$ Mn), by Region, 2015-2017
FIG 65: Celgene Corporation, Net Sales(%), by Products, 2017
FIG 66: Bellicum Pharmaceuticals, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 67: Bellicum Pharmaceuticals, Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 68: Bellicum Pharmaceuticals, Breakdown of Revenue Expenses (US$ Mn), by Collaboration and License Agreement, 2014-2017
FIG 69: Bellicum Pharmaceuticals, Breakdown of R&D Cost to Company (%), by Products in Pipeline, 2017
FIG 70: GlaxoSmithKline Plc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
FIG 71: GlaxoSmithKline Plc., Research & Development (US$ Mn) – Company Level, 2014–2017
FIG 72: GlaxoSmithKline Plc., Breakdown of Revenue Generation (US$ Mn), by Products, 2014-2017
FIG 73: GlaxoSmithKline Plc., Breakdown of Sales(%), by Region, 2017